Lifen Yao

Dr. Lifen Yao

First Affiliated Hospital of Harbin Medical University, Harbin, China
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Microbial Pathogenesis
Verified
Journal Article
Closed access
ZYZhenzhen Yan
Zhenzhen Yan
FYFan Yang
Fan Yang
JCJingwei Cao
Jingwei Cao
WDWencai Ding
Wencai Ding
SYShi Yan
Shi Yan
LYLifen Yao
Lifen Yao

17 September 2022 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
ZYZhenzhen Yan
Zhenzhen Yan
FYFan Yang
Fan Yang
LSLinlin Sun
Linlin Sun
JYJing Yu
Jing Yu
LSLina Sun
Lina Sun
LYLifen Yao
Lifen Yao

8 January 2024 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
XLXueying Li
Xueying Li
PQPusheng Quan
Pusheng Quan
YSYao Si
Yao Si
FLFei Liu
Fei Liu
YFYuwei Fan
Yuwei Fan
LYLifen Yao
Lifen Yao
Ferroptosis is an iron-dependent cell death mechanism involving the accumulation of lipid peroxides. As a critical regulator, glutathione peroxidase 4 (GPX4) has been demonstrated to be downregulated in epilepsy. However, the mechanism of ferroptosis in epilepsy remains unclear. In this study, bioinformatics analysis, analysis of epilepsy patient blood samples and cell and mouse experiments revealed strong associations among epilepsy, ferroptosis, microRNA-211-5p and purinergic receptor P2X 7 (P2RX7). P2RX7 is a nonselective ligand-gated homotrimeric cation channel, and its activation mainly increases neuronal activity during epileptic seizures. In our study, the upregulation of P2RX7 in epilepsy was attributed to the downregulation of microRNA (miR)-211-5p. Furthermore, P2RX7 has been found to regulate GPX4/HO-1 by alleviating lipid peroxidation induced by suppression of the MAPK/ERK signaling pathway in murine models. The dynamic decrease in miR-211-5p expression induces hypersynchronization and both nonconvulsive and convulsive seizures, and forebrain miR-211-5p suppression exacerbates long-lasting pentylenetetrazole-induced seizures. Additionally, in this study, induction of miR-211-5p expression or genetic-silencing of P2RX7 significantly reduced the seizure score and duration in murine models through the abovementioned pathways. These results suggest that the miR-211-5p/P2RX7 axis is a novel target for suppressing both ferroptosis and epilepsy.

2 April 2024 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
PQPusheng Quan
Pusheng Quan
XLXueying Li
Xueying Li
YSYao Si
Yao Si
LSLinlin Sun
Linlin Sun
FDFei Fan Ding
Fei Fan Ding
LYLifen Yao
Lifen Yao
The pathogenesis of Parkinson’s disease (PD) is strongly associated with neuroinflammation, and type I interferons (IFN-I) play a crucial role in regulating immune and inflammatory responses. However, the specific features of IFN in different cell types and the underlying mechanisms of PD have yet to be fully described. In this study, we analyzed the GSE157783 dataset, which includes 39,024 single-cell RNA sequencing results for five PD patients and six healthy controls from the Gene Expression Omnibus database. After cell type annotation, we intersected differentially expressed genes in each cell subcluster with genes collected in The Interferome database to generate an IFN-I-stimulated gene set (ISGs). Based on this gene set, we used the R package AUCell to score each cell, representing the IFN-I activity. Additionally, we performed monocle trajectory analysis, and single-cell regulatory network inference and clustering (SCENIC) to uncover the underlying mechanisms. In silico gene perturbation and subsequent experiments confirm NFATc2 regulation of type I interferon response and neuroinflammation. Our analysis revealed that microglia, endothelial cells, and pericytes exhibited the highest activity of IFN-I. Furthermore, single-cell trajectory detection demonstrated that microglia in the midbrain of PD patients were in a pro-inflammatory activation state, which was validated in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD mouse model as well. We identified transcription factors NFATc2, which was significantly up-regulated and involved in the expression of ISGs and activation of microglia in PD. In the 1-Methyl-4-phenylpyridinium (MPP+)-induced BV2 cell model, the suppression of NFATc2 resulted in a reduction in IFN-β levels, impeding the phosphorylation of STAT1, and attenuating the activation of the NF-κB pathway. Furthermore, the downregulation of NFATc2 mitigated the detrimental effects on SH-SY5Y cells co-cultured in conditioned medium. Our study highlights the critical role of microglia in type I interferon responses in PD. Additionally, we identified transcription factors NFATc2 as key regulators of aberrant type I interferon responses and microglial pro-inflammatory activation in PD. These findings provide new insights into the pathogenesis of PD and may have implications for the development of novel therapeutic strategies.

21 March 2023 in Computers in Biology and Medicine
Verified
Journal Article
Closed access
SYShi Yan
Shi Yan
YSYao Si
Yao Si
WZWenyang Zhou
Wenyang Zhou
RCRui Cheng
Rui Cheng
PWPingping Wang
Pingping Wang
LYLifen Yao
Lifen Yao

23 June 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
PQPusheng Quan
Pusheng Quan
KWKai Wang
Kai Wang
SYShi Yan
Shi Yan
SWShirong Wen
Shirong Wen
CWChengqun Wei
Chengqun Wei
LYLifen Yao
Lifen Yao
This study aimed to identify potential novel drug candidates and targets for Parkinson’s disease. First, 970 genes that have been reported to be related to PD were collected from five databases, and functional enrichment analysis of these genes was conducted to investigate their potential mechanisms. Then, we collected drugs and related targets from DrugBank, narrowed the list by proximity scores and Inverted Gene Set Enrichment analysis of drug targets, and identified potential drug candidates for PD treatment. Finally, we compared the expression distribution of the candidate drug-target genes between the PD group and the control group in the public dataset with the largest sample size (GSE99039) in Gene Expression Omnibus. Ten drugs with an FDR < 0.1 and their corresponding targets were identified. Some target genes of the ten drugs significantly overlapped with PD-related genes or already known therapeutic targets for PD. Nine differentially expressed drug-target genes with p < 0.05 were screened. This work will facilitate further research into the possible efficacy of new drugs for PD and will provide valuable clues for drug design.